Qiming Venture Partners

Qiming Venture Partners, established in 2006, is a leading China-based venture capital firm with offices in Shanghai, Beijing, Suzhou, Hong Kong, and Singapore. It manages multiple funds totaling $9.5 billion, focusing on early and growth-stage investments in the Technology and Consumer (T&C) and Healthcare industries. With a strong track record, over 200 portfolio companies have achieved exits, and over 70 have become unicorns or super unicorns. Qiming Venture Partners USA, founded in 2017, is its affiliate in Cambridge, Massachusetts, specializing in healthcare, therapeutics, and digital health investments. The firm is known for its deep technical expertise, hands-on operational support, and thought leadership in the venture capital industry.

Zhang Ao

Executive Director

Artavazd Arumov Ph.D

Principal

Cyrus Chan

Associate

Nan Chen

Principal

David Chu

Partner

Phil DiGiacomo

Principal

Anna French

Managing Partner

Yuxin Fu

Vice President

Jinda Gao

Principal

Kuantai Yeh

Partner

Robert Headley

Partner

Maykin Ho

Venture Partner

William Hu

Managing Partner

Duane Kuang

Co-Founder and Managing Partner

Nisa Leung

Managing Partner

Dingzheng Li

Vice President

Jing Liu

Vice President

Chang Liu

Associate

Bin Liu

Vice President

Biao Lu

Associate

Shuo Mao

Principal

Will McConnell

Principal

Gary Rieschel

Founder and Managing Partner

James Shen

Venture Partner

Motao Sun

Vice President

Amy Tang

Venture Partner

Yi Tang

Principal

Shiyu Wang

Partner

Rachel Wang

Venture Partner

James Wang

Venture Partner

Jing Wu

Partner

Gillian Xu

RMB funds CFO

Peter (Ming) Yin

Principal, Cleantech

Janet Yu

Partner

Oscar Zhang

Principal

Yafeng Zhou

Associate

Alex Zhou

Partner

Zhiyuan Zhou

Associate

Zhifeng Zhou

Managing Partner

Jing-Shan Hu Ph.D

Venture Partner of Healthcare

Phillip DiGiacomo Ph.D

Principal

Past deals in Series A

Weimei Health

Series A in 2025
Weimei Health is a provider of smart solutions for medical information technology

Xi'an Dunbo Medical Equipment

Series A in 2025
Xi'an Dunbo Medical Equipment focuses on the research, development, and production of AI medical devices. The products currently under development are cardiac pacemakers and brain pacemakers, Cardiac defibrillators. Self-developed products include chips, hardware circuits, software application systems, and structural materials.

Windward Bio

Series A in 2025
Windward Bio is a clinical-stage biopharmaceutical company dedicated to enhancing outcomes for patients with advanced immunological diseases, focusing on severe respiratory conditions. The company is advancing a fully human monoclonal antibody targeting thymic stromal lymphopoietin (TSLP) into Phase 2 clinical trials. This antibody, administered subcutaneously, potently binds to the TSLP ligand, extending its half-life and silencing its effector functions. Windward Bio is also developing innovative bispecific programs for other immunological disorders, aiming to address significant unmet medical needs in these areas. Led by an experienced team of biopharmaceutical executives, the company is committed to accelerating drug development to improve the lives of patients.

Matwings Technology

Series A in 2024
Matwings Technology is a biotechnology company that specializes in the design of functionally optimized proteins using advanced evolutionary methods. It focuses on the development of innovative drug molecular design through computational chemistry and artificial intelligence. Matwings collaborates with major pharmaceutical companies to conduct early-stage research and development of drugs targeting complex clinical challenges. The company's goal is to achieve breakthroughs in drug targets that are typically difficult to formulate, emphasizing the clinical value of its innovations.

Tianhu Technology

Series A in 2024
Tianhu Technology provides drug research and development services through independent collaborative closed-loop iterations, deeply integrating AI solutions with the drug development and production process. Tianhu Technology is an innovative drug R&D company that offers high-throughput phenotypic screening and physical computing technology, as well as AI solutions that are deeply integrated into the drug R&D process.

Bioyond Tech

Series A in 2024
Bioyond Tech utilizes robotics and artificial intelligence technology to provide a new generation of modular products and automation solutions for the life sciences sector.

Bytelumio

Series A in 2024
Bytelumio creates advanced all-optical networks that deliver high-speed connections of 800G and 1.6T for data centers.

Epigenic Therapeutics

Series A in 2024
Epigenic Therapeutics is a biotechnology company focused on developing gene editing therapies that leverage gene-silencing technology to address a range of diseases. The firm specializes in epigenome editing, aiming to regulate various conditions, including those related to ophthalmology, neurodegeneration, metabolism, and rare diseases. By creating innovative treatments, Epigenic Therapeutics seeks to offer effective solutions for patients suffering from chronic and severe health issues.

Candid Therapeutics

Series A in 2024
Candid Therapeutics is a biotechnology company specializing in the development of innovative therapies for immunological disorders. The company's primary focus is on creating novel, user-friendly treatments for autoimmune diseases. Their core technology involves advanced T-cell engager antibodies, which precisely redirect T-cells to selectively eliminate autoreactive B-cells, aiming to deliver transformative efficacy and improved therapeutic outcomes for patients.

Infinigence

Series A in 2024
Infinigence is dedicated to providing AGI computing power solutions based on its large model energy efficiency optimization tools, with the goal of resolving the challenge of efficient and unified deployment of large model algorithms to large computing power chips.

Guangjing Energy

Series A in 2024
Guangjing Energy specializes in the R&D and mass production of durable, large-area perovskite solar cell modules. They develops perovskite film printing technology with independent intellectual property rights and realized the preparation of large-area perovskite components.

Dr.Clear Aligner

Series A in 2024
Dr.Clear is an oral invisible orthodontic solution service provider that specializes in offering safe and comfortable digital solutions for face development management and invisible dental correction for children and adolescents.

CSR Biotech

Series A in 2024
CSR Biotech is a biological research company that specializes in super-resolution imaging technologies for living cells. The company focuses on the research, development, and manufacturing of advanced imaging instruments, providing a range of services such as customized cell sample generation, high-throughput detection, and imaging studies. Additionally, CSR Biotech offers image post-processing and quantitative analysis, along with high-dimensional spatio-temporal data visualization. These services are designed to support bio researchers in discovering new disease biomarkers and innovative drug targets, thereby enhancing the capabilities of scientific exploration in the field of biotechnology.

LTZ Therapeutics

Series A in 2024
LTZ Therapeutics is engaged in the development of innovative immunotherapies aimed at treating patients with cancer and other diseases that currently lack effective treatment options. The company employs reverse translational science and tumor biology, integrating these approaches with machine learning to advance its immunotherapy solutions. This strategy enables LTZ Therapeutics to create novel cancer treatments that address significant unmet clinical needs, ultimately striving to improve patient outcomes in the field of oncology.

Thorough Future

Series A in 2024
Thorough Future specializes in the integration of advanced technology within the medical sector, focusing on enhancing diagnostic services in clinical medicine. The company leverages artificial intelligence and big data to offer intelligent diagnosis and predictive services for pathology images. This innovative approach aims to improve diagnostic accuracy and efficiency, particularly for cancer patients, by providing personalized treatment recommendations. Through its commitment to integrating cutting-edge technology into healthcare, Thorough Future seeks to transform the way medical diagnoses are conducted and treatments are tailored.

Horizone Technologies

Series A in 2024
Horizone Technologies is membrane materials and excellent filtration solutions manufacturer focusing on the R&D and production

Pinnacle Medicines

Series A in 2024
Pinnacle Medicines is a peptide drug discovery company located in Doylestown, Pennsylvania. The company specializes in developing peptide-based therapeutics to address unmet medical needs. Utilizing AI-driven drug design tools, Pinnacle Medicines focuses on creating safe and effective treatments for medical applications. Through its innovative approach, the company aims to enhance the availability of convenient and reliable therapeutics for various health challenges.

Silicon Yi Technology

Venture Round in 2024
Silicon Yi Technology is a biotech firm specializing in RNA nanopesticide research and development designed to target pests and diseases.

Magair Chemical

Series A in 2024
Magair Chemical is a chemical synthesis CRO that was founded by Magera Technology. It is committed to using automated and intelligent platforms to provide new drug R&D customers with a new generation of chemical synthesis CRO services, significantly shortening the delivery of chemical synthesis links in the new drug R&D cycle, and significantly reducing the costs associated with chemical synthesis, removing pharmaceutical synthesis's current reliance on manual operations.

Supermag

Series A in 2024
Suzhou Supermag Intelligent Technology Co., Ltd. (hereinafter referred to as Suci Technology) is committed to the research and development, production and sales of maglev high-speed motors. With the design authorization of magnetic levitation compressors, magnetic levitation blowers, magnetic levitation pumps, etc., it provides core components such as magnetic levitation motors, magnetic levitation bearings, magnetic levitation controllers, and displacement sensors.

Swap

Series A in 2024
Swap is a company that makes a battery interchange system that is designed to replace the traditional charging process for electric motors. The company offers an energy switching system comprised of both energy stations and handmade batteries that can be used with the assistance of a mobile application, allowing users to supply speed and timeliness to bike riders at a low cost. The company aims to support the nation's zero-emission goal by providing the revolutionized charging infrastructure

ACXEL

Series A in 2024
ACXEL Tech specializes in large area electronics, focusing on digital microfluidic cell manipulation platforms that enhance drug discovery and biological research. By transforming active pixels into precise engines, ACXEL's technology enables the rapid transport of liquid droplets, facilitating complex experimental procedures at the single-cell level. This innovative approach supports various applications, including cell line development, cell therapy, synthetic biology, and antibody therapy. The platform's high throughput and low-cost design provide clients with the ability to increase productivity and efficiency in their research efforts across chemistry, biology, and medical technology.

Sano Dynamics

Series A in 2023
Sano Dynamics is a producer of hydraulic system core components and hydraulic industrial robots.

Infinigence

Series A in 2023
Infinigence is dedicated to providing AGI computing power solutions based on its large model energy efficiency optimization tools, with the goal of resolving the challenge of efficient and unified deployment of large model algorithms to large computing power chips.

Sanegene Bio

Series A in 2023
Sanegene Bio is engaged in the development of RNA interference (RNAi) therapeutics aimed at addressing unmet clinical needs across various therapeutic areas. The company’s RNAi drug discovery platform focuses on effectively knocking down disease-causing genes, utilizing advanced RNA technology to ensure specific delivery of multiple RNA drugs. This innovative approach allows for targeted treatment of patients suffering from a range of conditions, including cardiovascular and metabolic diseases, immunology-related diseases, infectious diseases, and disorders affecting the central nervous system and eyes. Through its comprehensive RNAi portfolio, Sanegene Bio seeks to provide effective therapeutic solutions for challenging health issues.

Tachem

Series A in 2023
Tachem is a biotechnology company that develops, produces, and distributes a range of products derived from the protected amino acid series. These products cater to diverse industries, including medical, healthcare, food, and cosmetics, serving as high-quality chemical raw materials and biotechnical solutions for various applications.

Shennapsi Artificial Intelligence Technology

Series A in 2023
Synapsor is a medical-grade wearable device research and development company, oriented to the AI+ medical and health field, and is committed to the development and manufacturing of AI-powered medical-grade smart wearable devices, including AI-ECG artificial intelligence. Diagnostic analysis system, CUMS uric acid blood glucose and cholesterol monitoring system, etc. The company has recently received tens of millions of yuan in Series B investment, and the investor is Xiaomi Technology.

Lixin Huigan

Series A in 2023
Lixin Huigan is a full-service manufacturer of sensors and an application service provider with an emphasis on the creation of premium micro-nanosensors.

Casela

Series A in 2023
Casela is a chip and semiconductor company

Congnitact

Series A in 2023
risk prediction, diagnostic, and disease monitoring tool for dementia, aiming to detect Alzheimer's disease

Inexbot

Series A in 2023
iNexBot specializes in the development and manufacturing of robot motion controllers and industrial robot intelligence technology. The company focuses on creating solutions for various sectors, including industrial robotics, collaborative robotics, semiconductors, healthcare automation, and automotive electronics. iNexBot's offerings encompass advanced robot motion control systems, machine vision technology, laser seam tracking technology, and other essential robot hardware. By providing both hardware and software, iNexBot equips robot manufacturers with the necessary tools to enhance their robotic products and improve operational efficiency across multiple industries.

CSR Biotech

Series A in 2023
CSR Biotech is a biological research company that specializes in super-resolution imaging technologies for living cells. The company focuses on the research, development, and manufacturing of advanced imaging instruments, providing a range of services such as customized cell sample generation, high-throughput detection, and imaging studies. Additionally, CSR Biotech offers image post-processing and quantitative analysis, along with high-dimensional spatio-temporal data visualization. These services are designed to support bio researchers in discovering new disease biomarkers and innovative drug targets, thereby enhancing the capabilities of scientific exploration in the field of biotechnology.

Epigenic Therapeutics

Series A in 2023
Epigenic Therapeutics is a biotechnology company focused on developing gene editing therapies that leverage gene-silencing technology to address a range of diseases. The firm specializes in epigenome editing, aiming to regulate various conditions, including those related to ophthalmology, neurodegeneration, metabolism, and rare diseases. By creating innovative treatments, Epigenic Therapeutics seeks to offer effective solutions for patients suffering from chronic and severe health issues.

P0x Labs

Series A in 2023
P0x labs is the team behind Manta Network is a privacy-preserving technology operating on the Polkadot blockchain.

AskGene Pharma

Series A in 2023
AskGene Pharma is a biotechnology company focused on developing innovative cytokine prodrugs to meet critical unmet medical needs in oncology and autoimmune diseases. The firm utilizes its advanced smart kine prodrug platform to fully harness the therapeutic potential of cytokine molecules, addressing significant challenges associated with current cytokine therapies. This platform is designed to avoid systemic pharmacokinetic sinks and modulate specific immune cells within the tumor microenvironment, thereby improving safety and efficacy. By leveraging cutting-edge research and development facilities, AskGene Pharma aims to deliver next-generation therapies that offer safer and more effective treatment options for patients.

Manta Network

Series A in 2023
Manta Network is focused on creating a secure and interoperable digital ecosystem through the use of Zero-Knowledge technology. The company operates a decentralized exchange platform designed to protect user privacy and prevent tracking of activities. By utilizing a protocol based on substrate frameworks, Manta Network offers end-to-end anonymity, high throughput, and robust cross-chain interoperability. This enables users to exchange data in a secure environment, prioritizing privacy and security in their transactions.

Tenpoint Therapeutics

Series A in 2023
Tenpoint Therapeutics is a biotechnology company dedicated to developing engineered cell-based therapies aimed at restoring vision for individuals affected by degenerative ocular diseases. The company leverages an innovative platform that includes in vivo reprogramming techniques, allowing for targeted delivery of therapeutic systems directly to the eye. This approach eliminates the need for systemic administration, which can improve treatment efficacy and patient outcomes. By focusing on vision restoration, Tenpoint Therapeutics strives to significantly enhance the quality of life for patients suffering from various eye conditions.

Guangjing Energy

Series A in 2023
Guangjing Energy specializes in the R&D and mass production of durable, large-area perovskite solar cell modules. They develops perovskite film printing technology with independent intellectual property rights and realized the preparation of large-area perovskite components.

Puanita

Series A in 2023
Puanita is a pet medicine brand seeking development with science and technology for pets. Puanita is headquartered in China.

Thorough Future

Series A in 2023
Thorough Future specializes in the integration of advanced technology within the medical sector, focusing on enhancing diagnostic services in clinical medicine. The company leverages artificial intelligence and big data to offer intelligent diagnosis and predictive services for pathology images. This innovative approach aims to improve diagnostic accuracy and efficiency, particularly for cancer patients, by providing personalized treatment recommendations. Through its commitment to integrating cutting-edge technology into healthcare, Thorough Future seeks to transform the way medical diagnoses are conducted and treatments are tailored.

CIX Technology

Series A in 2023
CIX Technology specializes in developing advanced intelligent computing solutions, focusing on high-performance, energy-efficient general-purpose computing chips and CPUs. Utilizing ARM architecture, the company designs its products for a variety of applications, including notebooks, desktops, high-end tablets, and augmented/virtual reality systems. By enhancing processing power, CIX Technology enables enterprises to create more efficient electronics and other technological products, ultimately improving computing speed and performance across various sectors.

HOUMO.AI

Series A in 2023
Houmo.AI is a semiconductor company founded in 2020 by Dr. Wu Qiang, specializing in integrated circuit storage technology tailored for artificial intelligence and high-power computing applications. The company focuses on developing intelligent computing chips that cater to the growing demand for computing power in the AI sector. By leveraging innovative technologies, Houmo.AI aims to deliver chips that offer significant performance improvements while maintaining low power consumption and affordability. This approach enables enterprises to manufacture advanced intelligent robotics and other AI-integrated electronics, ultimately striving to meet the challenges of true artificial intelligence.

Complete Omics

Series A in 2023
Complete Omics is a developer focused on multi-omics diagnostics aimed at the early detection of diseases, particularly cancer. The company specializes in personalized diagnosis and treatment, leveraging patented technologies across various omics fields. By offering precision companion diagnostics, Complete Omics enables researchers and pharmaceutical companies to conduct highly sensitive and specific health surveillance tests, facilitating improved patient outcomes through tailored medical interventions.

Zeen Health

Series A in 2023
Zeen Health is a digital therapeutics company that specializes in providing personalized mental health services through a mobile application. Founded in 2019 and headquartered in Shenzhen, China, the company utilizes artificial intelligence technology to deliver evidence-based mental health solutions. By focusing on the individual needs of users, Zeen Health aims to improve mental wellness through innovative digital approaches.

NFTGO

Convertible Note in 2023
NFTGo is a data aggregation platform focused on non-fungible tokens (NFTs), providing users with comprehensive information about the NFT market. The platform enables users to track and analyze NFT drops, rankings, and whale activity through its advanced search engine and market data tools. Utilizing a proprietary blockchain data collection engine, NFTGo gathers and processes the latest on-chain transaction data, presenting it in an accessible format for users to understand NFT trends and market dynamics. This facilitates NFT project stakeholders in accurately identifying potential customers while helping users navigate the evolving NFT landscape.

Joes Future Food

Series A in 2023
Joes Future Food engages the development, production, testing, and sales of raw and auxiliary materials for food and biological products.

Brise Pharma

Series A in 2023
Brise Pharma is a biopharmaceutical company dedicated to developing innovative drugs aimed at treating pain. The company focuses on creating highly differentiated analgesic treatments for various debilitating pain conditions, particularly targeting migraine, neuropathic, and musculoskeletal pain. By addressing significant unmet needs in pain management, Brise Pharma aims to enable healthcare providers to offer safe, effective, and accessible pain relief solutions for patients worldwide who suffer from poorly managed pain conditions.

Bioyond Tech

Series A in 2023
Bioyond Tech utilizes robotics and artificial intelligence technology to provide a new generation of modular products and automation solutions for the life sciences sector.

Qianshou

Series A in 2023
Qianshou is a dating application that helps to find the right partner for life by using artificial matchmaker service.

Deepway

Series A in 2023
Deepway is a manufacturer of smart vehicles focused on the truck freight market, offering advanced intelligent driving solutions. The company designs heavy-duty trucks characterized by low wind resistance and high-level intelligent driving capabilities. Its vehicles feature a distributed drive system with a modular design that operates on a unified hydrogen and electricity platform. This innovative approach allows the logistics industry to leverage smart freight systems, enhancing efficiency and sustainability in transportation.

Ricoton

Series A in 2023
Ricoton specializes in the development and production of medical devices aimed at treating or preventing cerebrovascular diseases. Founded in 2011 and based in Hunan, China, the company manufactures an array of intervention devices, including microcatheters, guidewires, and various tools for ischemic stroke treatment. Their product offerings feature a comprehensive three-piece set that includes a micro guide wire, micro catheter, and support catheter for vascular access, as well as a thrombectomy stent and balloon guide catheter. Ricoton's innovative solutions provide a one-stop thrombectomy option for patients, enhancing the effectiveness of cerebrovascular interventions.

TandemAI

Series A in 2023
TandemAI is an advanced technology company dedicated to reinventing drug discovery infrastructure. The company integrates proprietary AI-driven, high-performance computation with its efficient, large-scale in-house wet lab operations to deliver a turnkey drug discovery solution.

Xinchuangyuan Semiconductor

Series A in 2023
Xinchuangyuan Semiconductor is a manufacturing company of electronic equipment. Xinchuangyuan Semiconductor was founded in 2021 and was headquartered in Wuhan, China.

Swords & Dungeons

Series A in 2023
Swords & Dungeons is a developer of massively multiplayer online role-playing game (MMORPG) content, specializing in Web3 multi-chain game software. The company focuses on creating and updating interfaces for the gaming industry, offering decentralized games that provide engaging and social entertainment. By leveraging innovative technologies, Swords & Dungeons enables users to experience new types of gaming, making it a notable player in the evolving landscape of online gaming.

Biotree Technology

Series A in 2023
Biotree is a high-tech enterprise focused on the application and development of advanced research technology in the life sciences sector. It specializes in metabolomics, offering early detection and analysis services in China. The company boasts a core team with significant expertise in metabolomics, encompassing scientific research services, health testing, and industrial testing. Biotree emphasizes mass spectrometry and metabolic testing, continually innovating in metabolomics products and technologies. It holds several patents in this field and is recognized for its accomplishments in metabolomics detection and analysis. Over the years, Biotree has demonstrated consistent growth and has maintained profitability for six consecutive years, solidifying its position in the biotechnological testing and consulting services market.

Shennapsi Artificial Intelligence Technology

Series A in 2022
Synapsor is a medical-grade wearable device research and development company, oriented to the AI+ medical and health field, and is committed to the development and manufacturing of AI-powered medical-grade smart wearable devices, including AI-ECG artificial intelligence. Diagnostic analysis system, CUMS uric acid blood glucose and cholesterol monitoring system, etc. The company has recently received tens of millions of yuan in Series B investment, and the investor is Xiaomi Technology.

Veridise

Series A in 2022
Veridise is a blockchain security company that specializes in identifying and addressing vulnerabilities in various blockchain applications. Founded by a team of experienced researchers, Veridise is renowned for its expertise in auditing Zero-Knowledge Circuits, MetaMask Snaps, smart contracts, and various decentralized finance protocols. The firm employs a hybrid approach that combines traditional auditing methods with automated Web3 security tools, enabling it to uncover critical vulnerabilities that other firms may overlook. In the first half of 2023, Veridise identified over 100 high-severity bugs, demonstrating its effectiveness in enhancing blockchain security. The company also offers a comprehensive platform for automatically auditing smart contracts, allowing clients to implement formal methods for improved security and correctness in their blockchain projects.

Bio-Link

Series A in 2022
Bio-Link is a drug development company established in 2001 and headquartered in Shanghai, China. It specializes in providing bioprocessing solutions for the life science industry, focusing on the development and manufacturing of essential process equipment and consumables. These products are utilized in the production of vaccines, antibody drugs, cell therapy, gene therapy, and other biologics. Bio-Link's offerings encompass upstream cell culture, disposable dispensing reservoirs, downstream chromatography, ultrafiltration, and filtration, along with process development services. The company aims to deliver high-quality and innovative solutions that enhance the efficiency, safety, and competitiveness of the biopharmaceutical supply chain. Additionally, there are indications that Bio-Link may explore wearable technology aimed at elderly care.

Entact Bio

Series A in 2022
Entact Bio is a biotechnology company that is in the preclinical stages of developing medications to improve protein function. It was founded by a team with deep roots in deubiquitinase (DUB) biochemistry, chemical biology, disease biology, and small-molecule drug development. The company's proprietary EncompassTM platform was designed to create enhancement-targeting chimeric (ENTACTM) medicines. ENTACs take advantage of DUBs' ability to regulate proteins.

Reunion Biotech

Series A in 2022
Reunion Biotech focuses on the research and development and industrial transformation of medical hydrogels. The company is committed to becoming an international leading hydrogel technology platform. The current pipeline includes systemic solutions for tumor radiotherapy protection, wound repair, tumor embolization, and drug delivery.

BayOmics

Series A in 2022
BayOmics is a biotechnology company specializing in the commercial development of proteomics research. It focuses on the application of advanced biological and pharmaceutical technologies aimed at addressing critical illnesses. Utilizing integrated automated proteomics technology, BayOmics conducts functional proteome analyses and engages in the discovery of new drug targets. The company also supports targeted drug research and development based on micro-clinical samples. Through these efforts, BayOmics provides essential technical support to the medical industry, contributing to the advancement of treatments for cancer and other significant diseases.

Sanegene Bio

Series A in 2022
Sanegene Bio is engaged in the development of RNA interference (RNAi) therapeutics aimed at addressing unmet clinical needs across various therapeutic areas. The company’s RNAi drug discovery platform focuses on effectively knocking down disease-causing genes, utilizing advanced RNA technology to ensure specific delivery of multiple RNA drugs. This innovative approach allows for targeted treatment of patients suffering from a range of conditions, including cardiovascular and metabolic diseases, immunology-related diseases, infectious diseases, and disorders affecting the central nervous system and eyes. Through its comprehensive RNAi portfolio, Sanegene Bio seeks to provide effective therapeutic solutions for challenging health issues.

Sunny Dental

Series A in 2022
Sunny Dental, founded in 2007 and based in Beijing, China, specializes in a wide range of orthodontic and dental services. The company provides diagnosis and treatment for dental implants, children's dentistry, dental restorations, periodontal disease, and dental pulp issues. Additionally, it offers oral and maxillofacial surgery as well as invasive extraction services. Sunny Dental aims to deliver professional care in all aspects of dental health, catering to various patient needs.

PureVision

Series A in 2022
PureVision focuses on developing medical devices for ophthalmology. PureVision was founded in 2022 and was headquartered in Wenzhou, Zhejiang China.

PlusLife Biotech

Series A in 2022
PlusLife Biotech, founded in 2017 and based in Guangzhou, China, focuses on creating innovative molecular diagnostic tools and gene treatment programs utilizing advanced gene technology. The company has developed a range of molecular point-of-care testing (POCT) detection cards and reagents designed for diverse applications, including human respiratory and reproductive tract infections, genotype detection, and pet disease detection. PlusLife Biotech aims to provide customers with cost-effective and user-friendly testing solutions, enhancing the accessibility and efficiency of medical diagnostics.

Bitworx

Series A in 2022
Bitworx is a company based in Chengdu, China, specializing in product development and applications that leverage advanced algorithm and chip technology for communication, sensing, and detection. Currently, Bitworx is operating in stealth mode, which indicates that it is in the early stages of its business activities and may not yet be publicly disclosing its specific projects or technologies. The focus on communication and sensing technologies suggests a commitment to innovation in fields that require precise detection and data transmission capabilities.

Thorough Future

Series A in 2022
Thorough Future specializes in the integration of advanced technology within the medical sector, focusing on enhancing diagnostic services in clinical medicine. The company leverages artificial intelligence and big data to offer intelligent diagnosis and predictive services for pathology images. This innovative approach aims to improve diagnostic accuracy and efficiency, particularly for cancer patients, by providing personalized treatment recommendations. Through its commitment to integrating cutting-edge technology into healthcare, Thorough Future seeks to transform the way medical diagnoses are conducted and treatments are tailored.

Soda Health

Series A in 2022
Soda Health is a healthcare technology company founded in 2021 and based in Chicago, Illinois. The company focuses on addressing health inequities by leveraging social determinants of health. It offers a technology platform designed to assist individuals in identifying, accessing, and funding the resources necessary for a healthy life. By providing a system for administering and reimbursing personalized benefits, Soda Health enables customers to effectively bridge the gap between medical claims and retail payments, ultimately promoting better health outcomes.

Dezhen Technology

Series A in 2022
Dezhen Technology provides solutions for medical institutions to help hospitals develop clinical, and scientific research management. Dezhen Technology is headquartered in Hongkou, China.

XellSmart

Series A in 2022
XellSmart is a company based in Minhang District, Shanghai, China, focused on developing stem cell treatment solutions for various degenerative diseases that currently lack effective clinical treatments. The firm aims to enhance disease treatment and facilitate drug discovery through innovative stem cell therapies. XellSmart is dedicated to offering large-scale and cost-effective stem cell treatment, replacement, and transplantation options, specifically targeting major conditions like Parkinson's disease. By advancing these solutions, XellSmart seeks to provide patients with viable clinical alternatives to improve their health outcomes.

KouTech

Series A in 2022
KouTech develops surgical robots that can perform ophthalmic surgery, trans-gastroscopic, and general-purpose microsurgery. KouTech was founded in 2022 and was headquartered in Shanghai, China.

Deepway

Series A in 2022
Deepway is a manufacturer of smart vehicles focused on the truck freight market, offering advanced intelligent driving solutions. The company designs heavy-duty trucks characterized by low wind resistance and high-level intelligent driving capabilities. Its vehicles feature a distributed drive system with a modular design that operates on a unified hydrogen and electricity platform. This innovative approach allows the logistics industry to leverage smart freight systems, enhancing efficiency and sustainability in transportation.

OPUS

Series A in 2022
OPUS develops clinically applicable tissue engineering products and treatments.

GluBio Therapeutics

Series A in 2022
GluBio Therapeutics focuses on molecular glue-targeted protein degradation and provides a multi-dimensional protein degradation screening platform, an innovative target validation platform, a molecular glue rational design platform, and a proprietary library of highly active molecules.

P0xeidon Labs

Series A in 2022
P0xeidon Labs focuses on building web3 privacy, creating, and deploying tools.

Auron Therapeutics

Series A in 2022
Auron Therapeutics is a biotechnology company based in Wellesley, Massachusetts, dedicated to developing innovative therapies for cancer. Founded in 2018, the company aims to transform the treatment paradigm by shifting from traditional cell-killing approaches to differentiation therapy, which seeks to convert malignant cells into normal functioning cells. This strategy reactivates the body's inherent cellular programs to promote tumor maturation and restore normal tissue. Auron Therapeutics utilizes advanced platforms that integrate large omic datasets with high-throughput flow cytometry, enabling the rapid identification and validation of multiple therapeutic targets and drugs using primary human patient samples. Through its research, the company aspires to address unmet medical needs in oncology and provide life-saving treatments for cancer patients.

Biotree Technology

Series A in 2022
Biotree is a high-tech enterprise focused on the application and development of advanced research technology in the life sciences sector. It specializes in metabolomics, offering early detection and analysis services in China. The company boasts a core team with significant expertise in metabolomics, encompassing scientific research services, health testing, and industrial testing. Biotree emphasizes mass spectrometry and metabolic testing, continually innovating in metabolomics products and technologies. It holds several patents in this field and is recognized for its accomplishments in metabolomics detection and analysis. Over the years, Biotree has demonstrated consistent growth and has maintained profitability for six consecutive years, solidifying its position in the biotechnological testing and consulting services market.

Resunbio

Series A in 2022
Resunbio provides micro-nano processing research and development precipitation. Resunbio is headquartered in Longhua, China.

Crema Finance

Series A in 2022
Crema Finance is a developer of a concentrated liquidity protocol designed to enhance decentralized trading. The company offers services such as NFT farming, integrated aggregators, and Web3 infrastructure. Its innovative algorithm allows liquidity providers to concentrate their liquidity within specific price ranges, thereby facilitating more efficient trading. This approach not only reduces price slippage for traders but also empowers developers to integrate Crema Finance's services into decentralized applications (DApps), thereby strengthening the decentralized finance (DeFi) ecosystem.

AskGene Pharma

Series A in 2022
AskGene Pharma is a biotechnology company focused on developing innovative cytokine prodrugs to meet critical unmet medical needs in oncology and autoimmune diseases. The firm utilizes its advanced smart kine prodrug platform to fully harness the therapeutic potential of cytokine molecules, addressing significant challenges associated with current cytokine therapies. This platform is designed to avoid systemic pharmacokinetic sinks and modulate specific immune cells within the tumor microenvironment, thereby improving safety and efficacy. By leveraging cutting-edge research and development facilities, AskGene Pharma aims to deliver next-generation therapies that offer safer and more effective treatment options for patients.

HOUMO.AI

Series A in 2022
Houmo.AI is a semiconductor company founded in 2020 by Dr. Wu Qiang, specializing in integrated circuit storage technology tailored for artificial intelligence and high-power computing applications. The company focuses on developing intelligent computing chips that cater to the growing demand for computing power in the AI sector. By leveraging innovative technologies, Houmo.AI aims to deliver chips that offer significant performance improvements while maintaining low power consumption and affordability. This approach enables enterprises to manufacture advanced intelligent robotics and other AI-integrated electronics, ultimately striving to meet the challenges of true artificial intelligence.

Jiiov Technology

Series A in 2022
JIIOV Technology specializes in biometric recognition solutions, focusing on fingerprint identification products tailored for intelligent terminals. The company develops advanced algorithms for artificial intelligence fingerprint recognition, including specialized techniques for extreme finger fingerprints. In addition to its algorithmic innovations, JIIOV provides comprehensive design services encompassing sensor, optical, and module design, along with specialized computing solutions. This enables seamless integration of fingerprint functionality within various intelligent terminal applications, catering to the needs of law enforcement and software developers.

Tingsheng Technology

Series A in 2022
TINGSN develops Intracardiac echocardiography (ICE) catheter imaging technology designed to treat cardiac arrhythmia. In addition to ICE products, the company has developed its own heart internal catheter positioning and software algorithms and is developing China first computer surgical simulator for cardiac electrophysiology based on digital heart model.

GluBio Therapeutics

Series A in 2022
GluBio Therapeutics focuses on molecular glue-targeted protein degradation and provides a multi-dimensional protein degradation screening platform, an innovative target validation platform, a molecular glue rational design platform, and a proprietary library of highly active molecules.

Medmotion

Series A in 2022
Medmotion operates a comprehensive sports rehabilitation clinic in China, providing a range of specialized services aimed at enhancing recovery and performance. The clinic offers musculoskeletal system manipulation, imaging examination evaluations, and perioperative rehabilitation for orthopedic and sports-related conditions. Additionally, Medmotion focuses on conservative treatment and rehabilitation for trauma and sports injuries, as well as the development of digital customized orthopedic braces. The clinic also addresses common occupational diseases and offers professional guidance on sports protection. By delivering efficient sports rehabilitation services and expert sports medicine advice, Medmotion aims to significantly shorten recovery times for its clients.

Wowjoy Technology

Series A in 2022
WOWJOY TECHNOLOGY, based in Hangzhou, China, specializes in data-driven medical services through an internet-based platform. The company offers a range of informational technology solutions tailored for large hospital groups and their patients. Its services include integrated workstations for medical, imaging, laboratory, and pharmacy functions. By streamlining information processing procedures, WOWJOY TECHNOLOGY aims to enhance the efficiency of diagnosis, treatment, and billing in the healthcare sector.

Cencorp Automation

Series A in 2022
Cencorp Automation is a provider of process automation solutions focused on the electronics industry. The company offers a diverse range of equipment solutions including depaneling, odd-form assembly, test handling, laser marking, laser welding, and final assembly. Their innovative automation platforms are designed to enhance productivity and quality for their customers, which include leading firms in car electronics, telecommunications, and industrial electronics. By delivering tailored solutions, Cencorp Automation significantly improves the efficiency of customers' production processes.

Xiaoniao Kuaiyan

Series A in 2022
Xiaoniao Kuaiyan, headquartered in Beijing, China, offers home physical examination services that include regular health check-ups, tumor screenings, infection tests, chronic disease surveillance, and customized testing options for clients. In addition to these health services, the company also facilitates business cooperation between enterprises and provides customer service and professional training. Xiaoniao Kuaiyan is involved in formulating management procedures for quality inspection work and develops a product knowledge base to enhance its service offerings.

Ceptur Therapeutics

Series A in 2022
Ceptur Therapeutics is focused on developing innovative genetic medicines aimed at addressing diseases that currently lack effective treatments. The company utilizes its proprietary U1 Adaptor technology, which enables long-lasting and non-genotoxic silencing of disease-causing genes, particularly in challenging tissues beyond the liver and central nervous system. This technology addresses the limitations of existing gene silencing methods and holds promise for cancer treatment, allowing healthcare providers to offer new therapeutic options for patients with various types of cancers.

Axera

Series A in 2022
Axera is a high-tech semiconductor company specializing in the development of advanced artificial intelligence (AI) System-on-Chips (SoCs) for computer applications. The company's flagship product is an AI chip designed to excel in visual processing tasks, offering superior performance at low power consumption and latency, while maintaining high integration capabilities. This enables clients to perform real-time video analysis on devices, capture high-quality videos, and integrate multiple cameras efficiently with reduced costs.

MKSEMI

Series A in 2022
MKSEMI is a low-power ultra-wideband (UWB) company, provides a complete high precision location solution for device OEMs and ODMs.

Ruining Bio

Series A in 2022
Ruining Bio provides clinical medical solutions such as tumor radiotherapy protection, wound repair, tumor embolization, and anti-tumor drugs. Ruining Bio brings together various professionals in materials, chemistry, biomedical engineering, and clinical medicine.

SUPERHEXA

Series A in 2021
Superhexa is a hardware company based in Beijing, founded on October 15, 2020, by Xia Yongfeng. It specializes in the development of personal consumer electronics, aiming to integrate technology seamlessly into everyday life. By focusing on innovation, Superhexa seeks to enhance the user experience and adapt to the evolving needs of consumers.

Xinchuangyuan Semiconductor

Series A in 2021
Xinchuangyuan Semiconductor is a manufacturing company of electronic equipment. Xinchuangyuan Semiconductor was founded in 2021 and was headquartered in Wuhan, China.

Gemsouls

Series A in 2021
Gemsouls is a developer of an artificial intelligence platform that enables virtual characters to interact with the real world. The company aims to create an innovative experience for fans, allowing them to engage with their favorite characters and maintain lasting connections with both fictional and real-life figures. By leveraging AI technology, Gemsouls facilitates meaningful interactions, enhancing the ways individuals can relate to and enjoy their beloved characters.

Allorion Therapeutics

Series A in 2021
Allorion Therapeutics is a small molecule therapeutic development company dedicated to creating innovative treatments for cancer and autoimmune diseases. With operational facilities in Natick, Massachusetts, and Guangzhou, China, Allorion specializes in developing mutant selective and isoform-specific drugs through unconventional methods targeting established disease pathways. This approach aims to enhance the efficacy of treatments and reduce the likelihood of resistance in patients, contributing to improved therapeutic outcomes.

Supermag

Series A in 2021
Suzhou Supermag Intelligent Technology Co., Ltd. (hereinafter referred to as Suci Technology) is committed to the research and development, production and sales of maglev high-speed motors. With the design authorization of magnetic levitation compressors, magnetic levitation blowers, magnetic levitation pumps, etc., it provides core components such as magnetic levitation motors, magnetic levitation bearings, magnetic levitation controllers, and displacement sensors.

Cubenergy Technology

Series A in 2021
Cubenergy Technology is an energy technology company specializing in energy data operation services and the integration of distributed energy storage systems. The company develops advanced Energy Management Systems that utilize data analysis to optimize the performance of energy storage systems. By focusing on efficient control mechanisms, Cubenergy Technology aims to enhance system efficiency and provide users with effective energy management solutions.

V Light

Series A in 2021
Shimmer is an app that provides companionship. Whether chatting, watching videos, playing games, or singing karaoke, it can all help in finding a chat topic.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.